Product Update for GARDASIL®9 (October 2018)


Merck recently announced that the US Food and Drug Administration (FDA) has approved an expanded age indication for GARDASIL 9, Merck's 9-valent human papillomavirus (HPV) vaccine. GARDASIL 9 is now approved for use in appropriate patients ages 9 through 45 years to help protect against certain HPV-related cancers and diseases. The previous indication for GARDASIL 9 was for appropriate 9- to 26-year-olds. 

For more information please contact your Merck Vaccine Representative or call Merck Vaccine Customer Center at 1-877-829-6372.

Please also review Merck's GARDASIL 9 Product Update Announcement for details on indication, dosing schedule, packaging, CPT code, and NDC Number.

To view CCPAPP's contracted pricing for Merck's GARDASIL 9 and other vaccine products, please visit the pricing page of our website. Please email if you are in need of your practice's account login information.


« Back